A means of reducing exocrine insufficiency of the pancreas in chronic pancreatitis

 

(57) Abstract:

The invention relates to gastroenterology. The purpose of the invention effective recovery vneshnepoliticheskoi functions and increase remission in chronic pancreatitis. This goal is achieved by the course introduction of the drug "Antepost f". 1 Il. table 2.

The invention relates to medicine, namely to a gastroenterologist, and can be used for the treatment of exocrine pancreatic insufficiency (PI) of patients with chronic pancreatitis (CP).

There are many different medicines for the treatment of exocrine insufficiency PJ patients with chronic pancreatitis. In particular, it is recommended that the enzyme preparations: festal, digital, Mezim-Forte, Pancreatin, pansinin, cotazym-Forte, Oraza, polysim, pencemaran (1, 2); balanced amino acid mixture: livesin, amine, polyamine; methylxanthines: a 2.4% solution of aminophylline, theophylline, Teodor, Teodor, toolong; 10% solution of calcium gluconate (2).

However, none of these drugs have no effect on the primary ductal mechanism of pathogenesis of CP, therefore, achieved clinical effect unexpressed and neston enzymes contributing to the consolidation of exocrine insufficiency mud.

The purpose of the invention: efficient recovery of exocrine functions mud and increase remission in chronic pancreatitis.

The objective is achieved by intravenous drip infusion "antepost f" that meets the criteria of "novelty" and "significant differences". First the drug is diluted in 400 ml of saline and injected slowly 30-40 drops in 1 minute At increasing the speed of the introduction of possible headache, shortness of breath. The initial dose is 0.01-0.02 μg/kg patient weight. With the introduction of the drug in smaller doses, the clinical effect is not achieved. The introduction of the drug in higher doses can cause pain in the upper floor of the abdomen. The dose of each subsequent administration of the drug is gradually increased to 0.04-0.05 mg/kg It is necessary to obtain a more stable clinical effect. In cases where the dose of the drug in re-introductions have not been raised or increased less than 0.04 µg/kg body weight of the patient, the clinical effect was less pronounced. The average duration of remission in this group of patients (9 people) sostoianie) means 8,43,3 months. and however much lower than in the group of patients (15 people) with the dose repeated injections of the drug gradually increased to 0.04-0.05 mg/kg 17,53,7 months. (p < 0,05). With further increase in dose entoprocta f more than 0,06 µg/kg in patients often appeared headaches, shortness of breath, and women sometimes besides dragging pain in the abdomen.

The drug was administered every other day. Daily introduction sometimes appeared the same symptoms as increasing the dose of entoprocta f more than 0,06 µg/kg treatment consisted of 7-10 injections of the drug. Reducing the number of injections (up to 6 or less) reduced growth of exocrine gland activity and duration of remission. The increase in the number of injections of the drug for more than 10 did not lead to further growth of the exocrine activity of the gland and duration of remission. Thus, the proposed dosage, speed, quantity and mode of administration of entoprocta f with the above purpose seems to be the most optimal. At least 3 days canceled all drugs. Cancel laxatives, such as gloxina, castor oil less than 3 days or accidental reception of the latter on the background of the introduction of esposta f patients with chronic pancreatitis leads to reduction of exocrine pancreatic insufficiency and increase the duration of remission, as demonstrated by the following studies. On exocrine functions PJ tried to increase its exocrine activity after the first injection and after injection of entoprocta f in the initial dose of 0.01-0.02 mg/kg after treatment. With this purpose, conducted simultaneous gastroduodenal sensing using dual-probe. Through the gastric channel probe constantly aspiration to exclude pankraticheskoi stimulation. Within 20 min was collected basal portion of the pancreatic juice, then began the introduction of entoprocta F. After the start of administration of the drug continued to duodenal aspirate the contents, but for the study took 20 minutes serving with the 60th 80 th minute, because this time is the peak maximum of the exocrine activity of the mud. stimulated antiproton F. Hermetically sealed test tubes with samples were placed on ice. The amylase activity was determined by the method of Caraway, lipase by Bondi in the modification M. S. Rozhkova, trypsin by Anson Worldly in its own modifications, bicaronate by the method of back titration. In table.1 presents the indicators exocrine activity of the mud boldrocchi f significantly increased exocrine activity of the mud. The reaction exocrine Department gland healthy individuals and patients with CP on homogeneous introduction of entoprocta f (at a dose of 0.4 mcg/kg/min during 50 min) are presented in table.2, in the drawing. From which it follows that the introduction of entoprocta f healthy people leads to a rapid increase in the separation of enzymes, bicarbonate and water. In CP patients, the response of the gland to the introduction of this drug, in principle, was not different from that in healthy, but was characterized by a lower increase in the above parameters.

Analysis of the results presented in table.2 shows that entoproct f moderately induces the enzymatic function of the mud, however, significantly increase its ductular cells (sharply and significantly increases the secretion of water and bicarbonate). Thus, entoproct f is moderate stimulator of secretion of enzymes and potent stimulator of secretion of bicarbonate and water pancreas. This circumstance considering doctolero theory of the pathogenesis of chronic pancreatitis (presence of protein and calcium tubes in pancreatic ducts) and served as the basis for the application of entoprocta f with the above purpose. The calculation was done on a "flush", or rather the drainage ducts liquid mud faction who is, what patogeneticaly effects of the drug caused the lengthening of the period of remission is almost 1.5 times, significantly reducible signs of exocrine pancreatic insufficiency in patients with chronic pancreatitis.

The proposed tool will allow to increase the efficiency of recovery of exocrine functions of the pancreas and increase the period of remission in chronic pancreatitis.

The use of entoprocta-f as a means of reducing exocrine insufficiency of the pancreas in chronic pancreatitis.

 

Same patents:

The invention relates to medicine and can be used to treat conditions involving increased adhesion - aggregation of platelets and for preservation of platelet-rich plasma

The invention relates to medicine, namely to obstetrics

FIELD: veterinary science.

SUBSTANCE: a sow should be twice injected with oxytocin and, additionally, intramuscularly about 2-4 h after afterbirth detachment one should introduce clathroprostin at the dosage of 1 ml. The innovation suggested is very efficient in preventing metritis-mastitis-agalactia and endometritis in sows, as well.

EFFECT: higher efficiency of prophylaxis.

1 ex, 1 tbl

FIELD: animals science.

SUBSTANCE: the present innovation deals with intramuscular injection of sodium salt preparation cloprostenol 30-45 min before placing at the dosage of 750 mcg/animal. The method provides increased reproductive function, enhances sexual reflex, increases the volume of ejaculate, concentration, activity and quality of spermatozoa.

EFFECT: higher efficiency of breeding.

2 ex, 3 tbl

FIELD: organic chemistry, medicine.

SUBSTANCE: invention relates to 1-ethanolamide PGF of formula I useful in relaxation of mammalian intraocular pressure. Claimed substance unlike majority of ocular hypotensive prostaglandins doesn't effect through FP-receptor.

EFFECT: new effective compound for relaxation of mammalian intraocular pressure.

4 cl, 1 ex, 16 dwg, 16 tbl

FIELD: medicine, chemical-pharmaceutical industry.

SUBSTANCE: invention relates to new applying EP4 receptors agonist for treatment and/or prophylaxis of diseases associated with loss of osseous mass. Agonists of EP4 receptors show high effectiveness in treatment of diseases associated with loss of osseous mass, among the, as osteoporosis of different genesis. Agonists of EP4 receptors involve prostaglandin skeleton base.

EFFECT: valuable medicinal properties of pharmaceutical composition.

16 cl, 3 tbl, 5 ex

FIELD: medicine, obstetrics.

SUBSTANCE: invention relates to a method for treatment of delivery activity weakness. Method involves simultaneous administration of prostaglandin F in the concentration 12.5 mcg/ml at the rate 8 mcg/min and adenosine triphosphate sodium in the concentration 0.25 mcg/ml at the rate 0.25 mcg/min. Infusion continues up to end of the second stage of delivery. Method provides enhancing the delivery activity, increasing rate of uterine orifice opening on the background of the reduced dose of prostaglandin.

EFFECT: improved treatment method.

3 ex

FIELD: chemico-pharmaceutical industry.

SUBSTANCE: the suggested composition contains prostaglandin-like compound as an active component and it , also, deals with the method to treat disorders of external secretion that includes application of efficient quantity of prostaglandin-like compound for a person who needs such a treatment. The composition is of high efficiency at treating disorders inactivity of lacrimal and sudoriferous glands being of high bioavailability and nontoxic.

EFFECT: higher efficiency of therapy.

33 cl, 5 ex, 7 tbl

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to a purgative agent composition comprising bicyclic compound of the formula (1) and a method providing the purgative effect and using compounds of the formula (1). He composition possesses the enhanced effectiveness.

EFFECT: valuable medicinal properties of composition.

42 cl, 3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves applying cannabinoid receptor agonists for treating for transitory relaxation of lower esophageal sphincter and states like gastroesophageal reflux disease, regurgitation, preventing reflux or insufficient mass increase caused by the relaxation.

EFFECT: enhanced effectiveness of treatment.

18 cl, 3 tbl

FIELD: medicine, ophthalmology.

SUBSTANCE: method involves administration of the preparation "Ginkor-Fort" in the dose 1 tablet, 2 times per a day for 2 weeks and after one month break the preparation "Diovenor" is administrated in the dose 1 tablet, once per a day for 2 weeks at the constant instillation of the preparation "Ksalatan" in the dose 1 drop, once time before night. Such schedule of the method provides the stable normalization of intraocular pressure based on improvement of venous orbital and cerebral circulation. Invention is designated for medicinal treatment of glaucoma discirculatory variant.

EFFECT: improved method of treatment.

2 tbl, 1 ex

FIELD: medicine, ophthalmology.

SUBSTANCE: the diagnostics of primary open-angle glaucoma (POAG) should be carried out at fulfilling unloading diagnostic sample based upon evaluation of the dynamics of the data of computed static perimetry. At detecting alterations in the parts of vision field being characteristic for glaucomatous process it is necessary to conduct unloading sample: after preliminary control of intra-ocular pressure it is important to apply per 1 drop of ophthalmological preparation "Travatan" retroblepharally and in 24 h one should carry out control measurement of intra-ocular pressure and repeat computed static perimetry. In case of improved retinal sensitivity at the background of decreased intra-ocular pressure the sample should be considered to be positive and POAG diagnosis should be established. The innovation enables to prescribe selective hypotensive therapy in due time.

EFFECT: higher accuracy and efficiency of diagnostics.

3 ex

Up!